Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.
Location: United States, Massachusetts, Woburn
Employees: 11-50
Total raised: $52M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 12.01.2023 | Korea Inve... | partners.k... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.11.2022 | Series A | $52M | - |
Mentions in press and media 12
| Date | Title | Description |
| 30.11.2022 | Cambridge-based pharmaceutical startup Rgenta Therapeutics raises USD 52 million in Series A funding | CAMBRIDGE, Mass., Nov. 29, 2022 — Rgenta Therapeutics Inc. today announced the completion of a USD 52 million Series A round-headed by AZ-CICC Healthcare Investment Fund, with participation from all current and new investors, including Kore... |
| 29.11.2022 | Rgenta Therapeutics Raises $52M for Integrative RNA-Targeting Discovery Platform | What You Should Know: Only a quarter of the proteins implicated in human diseases are currently druggable by traditional approaches for developing small-molecules compounds. Thus, new approaches directly targeting messenger RNAs of disease ... |
| 29.11.2022 | Rgenta Therapeutics Scores $52M Series A | CAMBRIDGE, MA, Rgenta Therapeutics announced today that it closed a $52 million Series A round. >> Click here for more funding data on Rgenta Therapeutics >> To export Rgenta Therapeutics funding data to PDF and Excel, click... |
| 29.11.2022 | Rgenta Therapeutics Raises $52M in Series A Financing | Rgenta Therapeutics, a Cambridge, MA-based biotechnology company, raised $52M in Series A funding. The round was led by AZ-CICC Healthcare Investment Fund with participation from Korean Investment Partners, Delos Capital. The company plans ... |
| 26.05.2021 | China Digest: Lilly Asia Ventures backs Rgenta; IntoCare nets $15m | China-headquartered Lilly Asia Ventures has backed an $18 million seed extension round for US-based Rgenta Therapeutics. In a separate development, IntoCare Medical Technology (Suzhou) Co., Ltd has raked in nearly 100 million yuan ($15 mill... |
| 26.05.2021 | China Digest: Lilly Asia Ventures backs Rgenta; IntoCare nets $15m | Premium China-headquartered Lilly Asia Ventures has backed an $18 million seed extension round for US-based Rgenta Therapeutics. In a separate development, IntoCare Medical Technology (Suzhou) Co., Ltd has raked in nearly 100 million yuan (... |
| 25.05.2021 | Rgenta Therapeutics Announces the Successful Completion of Extension of Seed Financing | |
| 25.05.2021 | Rgenta Therapeutics : Announces the Successful Completion of Extension of Seed Financing | CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Rgenta Therapeutics announced today that it closed an $18 million seed extension round and welcomed Lilly Asia Venture (LAV) and Vivo Capital as new investors to the syndicate. Rgenta Therapeut... |
| 04.04.2020 | Rgenta Therapeutics Scores $20M Seed Round | CAMBRIDGE, MA, Rgenta Therapeutics announced it has closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. >> Click here for more funding data on Rgenta Therapeutics >> T... |
| 02.04.2020 | Rgenta Therapeutics Launches with $20M Seed Investment | Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelh... |
Show more